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Abstract
Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory
ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well
as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral
body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of
intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix
MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with
no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recov-
ery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to “D”. This case supports
further investigation into allogeneic-based stem cell therapies for SCI.
Introduction
Approximately 12,000 new cases of spinal cord injury
(SCI) occur per annum in the US, with about 300,000
patients living with neurological consequences [1].
Post-injury medical interventions are aimed at treat-
ment of complications such as autonomic dysreflexia,
pain, and urinary tract infections. Regenerative
approaches using growth factors and various cell
therapies are particularly appealing with early clinical
reports of improvement using autologous bone mar-
row cells [2-4], olfactory ensheathing cells [5,6], and
Schwann Cells [7]. In this manuscript we will describe
some of the cellular/molecular aspects of spinal cord
injury and regeneration, followed by overviewing
selected preclinical and clinical interventions in order
to provide a background for the rationale of cellular
therapy for SCI. We will subsequently describe a
combination approach that has yielded promising
results in a case report, with the hope of stimulating
further research into such allogeneic combination
approaches.
SCI Background
Nerve damage in SCI occurs in the majority of cases as a
result of the combined effects of the initial physical injury,
and subsequent inflammatory response caused in part by
physical damage to the blood brain barrier, immune cell
response to injury, and local ischemia. Typical causes of
injury include contusive, compressive or stretch damage
which is associated with severing of axons at the nodes of
Ranvier, leading to axon retraction [8]. Furthermore,
axons proximal to the area of injury that do not retract are
known to develop abnormalities such as loss of myelina-
tion and swelling of the axonal body, resulting in loss of
excitability [9]. Demyelination is in part believed to result
from death of oligodendrocytes surrounding the axon, a
process which occurs even at 3 weeks after the initial
injury [10]. Importance of demyelination in this process is
seen in experiments where remyelination induced by
administration of Schwann cells has been demonstrated to
elicit benefit in animal models of SCI [11]. Mechanistically,
oligodendrocyte death appears to be related to the death
receptor Fas based on: a) Pattern of expression is tempora-
rily correlated with oligodendrocyte apoptosis in SCI mod-
els [12]; b) Genetic inactivation of Fas results in reduced
oligodendrocyte death [13]; and c) Administration of solu-
ble Fas [14] has a protective effect on SCI associated
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umbilical cord blood stem cells in a rat SCI model results
in therapeutic benefit which seems to be mediated by
reduction of Fas expression [15]. Death of neurons them-
selves subsequent to SCI is associated with release of glu-
tamate and other excitotoxins such as free ATP [16-18].
Interestingly, excitotoxicity occurs not only as a result of
initial injury, but has also been implicated in secondary,
more long-term, neuronal damage [19].
Associated with demyelination is the exposure of
potassium channels which causes accumulation of the
ion intraneuronally, thus further modifying ability to
transmit electrical signals [20]. Inhibition of fast acting
potassium channel channels using 4-aminopyridine has
demonstrated some therapeutic effects in animal models
of SCI [21,22], and in clinical trials [23-25].
Thus the initial injury process seems to cause: a)
direct transection of neurons; b) inflammatory responses
that stimulate a self-perpetuating cascade of axon retrac-
tion; c) inflammatory mediated death of oligodendro-
cytes; and d) stimulation of mediators such as NOGO
that prevent endogenous axonal reattachement. Having
described in general terms the cause of pathology, we
will now overview some of the mechanisms by which
the host responds to injury.
Endogenous Regenerative Processes
Subsequent to spinal cord injuries, Schwann cells originat-
ing from the spinal root traffic to the area of injury and
initiate a process of remyelinating injured axons [26]. An
endogenous progenitor cell type, termed the ependymal
cell, was observed in early studies to proliferate after spinal
cord transection in animal models [27]. These cells, which
reside in the ependyma, are known to be active in regen-
eration in embryonic life but their activity diminishes in
adulthood [28]. A study in rats with SCI or intense exer-
cise demonstrated BRDU incorporation into the ependy-
mal cells under both conditions. Furthermore, the study
demonstrated that ependymal cell mitosis is associated
with increased proliferation and differentiation primarily
into macroglia or cells with nestin phenotype [29]. It
appears that ependymal cells purified from rats that
underwent spinal cord injury proliferate in vitro almost
10-fold faster than ependymal cells from control animals,
thus suggesting an injury-associated mitogenic event.
Furthermore, in the same study it was demonstrated that
transplantation of undifferentiated ependymal cells or dif-
ferentiated oligodendrocyte precursor cells generated from
ependymal cells, when administered to a rat model of
severe spinal cord contusion induced recovery of motor
activity 1 week after injury [30]. Using genetic cell fate
mapping, it was demonstrated that primarily all neuro-
genic cells present post SCI are derived from ependymal
cells, including glial cells associated with scar tissue, as
well as a smaller number of oligodendrocytes [31]. Epen-
dymal cells are known to react to exogenous growth fac-
tors, for example, intrathecal administration of EGF and
FGF-2 was demonstrated to induce their proliferation
[32]. Thus one therapeutic approach may be administra-
tion of exogenous factors that stimulate/accelerate natural
remyelination processed. Indeed administration of FGF-2
has been demonstrated to improve locomotor function in
a rat SCI model [33].
Although at a cellular level various endogenous regen-
erative processes may be seen in the CNS, at a functional
level, post-injury regeneration is very limited. For example,
after axons are severed or damaged, the myelin compo-
nent of the axon is released into the extracellular environ-
ment where it generates inhibitors of neurite outgrowth
[34]. Inhibitors include Nogo-A, myelin-associated glyco-
protein (MAG) and oligodendrocyte myelin glycoprotein
(OMgp). All three of these proteins bind to the same
receptor, the Nogo-A receptor [35], and inhibit growth
cone migration towards the area of injury. Inhibition of
this receptor using antagonists has been demonstrated to
accelerate post-SCI healing in a rat model [36].
Another inhibitor of post-injury axon repair are the
reactive astrocytes that modify the ECM through secretion
of factors such as chondroitin sulfate proteoglycans
(CSPGs), including NG-2, neurocan, brevican, phospha-
can, and versican [37,38]. These proteoglycans, specifically
their side chains, are known to inhibit nerve growth and
in some cases contribute to formation of the glial scar that
serves as a physical barrier to axon regrowth [39]. Admin-
istration of the enzyme chondroitinase ABC, which cleaves
these side chains has been demonstrated to reduce axon-
inhibitory activity of CSPGs in vitro [40]. In vivo studies
demonstrated that condroitinase ABC therapy accelerates
recovery in animal models of SCI [41]. Supporting the
hypothesis that chondroitinase ABC benefits on SCI are
mediated by “inhibiting the inhibitor” of neurite out-
growth, a recent study demonstrated that treatment with
the enzyme provides a therapeutic window in which reha-
bilitation programs function optimally [42].
Angiogenesis is an integral part of numerous healing
processes. In the context of spinal cord injury, hypoxia
inducible factor (HIF)-1 alpha activates numerous
downstream effectors such as BDNF, VEGF, SDF-1, TrkB,
Nrp-1, CXCR4 and NO, that attempt to restore the “neu-
rovascular niche” after damage has occurred [43]. These
molecules act not only on creation of new vasculature but
also are involved in neurogenesis. The critical link between
neural recovery and angiogenesis may be seen in animal
models of post-stroke regeneration where cord blood
derived cells appear to elicit effects primarily by stimulat-
ing de novo vasculature which causes expansion of endo-
genous progenitors [44]. Transfection of neuronal
progenitors with the angiogenic factor VEGF has been
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tionally, administration of human CD133 peripheral blood
progenitor cells accelerates post-injury healing in part
through secretion of VEGF [46]. There is some evidence
that counter-angiogenic mechanisms are present in the
late post-injury setting. For example Mueller et al showed
that approximately 7 days post injury an accumulation of
endostatin/collagen XVIII is observed in the areas asso-
ciated with vascular remodeling [47].
Thus several endogenous repair mechanisms exist
including activation of ependymal cells and generation
of oligodendrocyte progeny, and angiogenesis. These are
inhibited in part by production of various agents such as
NOGO and ECM degradation productions. Tipping the
balance in favor of regeneration by exogenous growth
factor administration or providing inhibitors of inhibi-
tors is a promising approach. By understanding the
background biological post-injury terrain administration
of exogenous stem cells may be used for optimal results.
Stem Cell Therapy for SCI
Olfactory Ensheathing Cells
Given an endogenous reparative component, albeit mild,
exists in the injured CNS, an aim of research is to aug-
ment this process. Initial work in the 1980s focused on
providing a “bridge” for axon growth across the scar tis-
sue formed as a result of injury. Aguayo et al placed auto-
logous sciatic nerve grafts between the lower cervical/
upper thoracic spinal cord and the medulla oblongata in
injured mice and rats. At 1-7 months after grafting,
microscopic studies demonstrated myelinated axons had
migrated and grown across the graft. Horseradish peroxi-
dase was injected intraxonally to demonstrate functional
integrity of the axons [48]. Electrophysiological improve-
ments after excision of the spinal cord dorsal columns
was noted 5-6 months after application of peripheral
nerve graft across the injured area [49]. Work on using
grafted cells led to interest in olfactory ensheathing cells
as a potential source of glial cells for transplantation.
These cells function on the one hand to physically wrap
up numerous axons to form large bundles of axons, and
on the other hand are known to produce high levels of
axon-regenerating growth factors [50,51]. Olfactory
ensheathing cells have the unique property of being able
to repeatedly migrate from the nasal olfactory mucosa,
which is part of the peripheral nervous system into the
central nervous system environment of the olfactory bulb
[52]. This is in contrast to Schwann cells which are much
slower at integrating into the central nervous system.
Several studies have shown that combinations of olfac-
tory ensheathing cells with Schwann cells causes additive
therapeutic effects [53-55].
Purification of olfactory ensheathing cells can be per-
formed by selection for cells expressing the O4 antigen
but lacking expression of galactocerebroside. These cells
appear to have a unique phenotype in contrast to other
glial cells or Schwann cells, for example, they have
astrocyte markers and lack a basal lamina and collagen
fibrils [56,57]. Administration of olfactory ensheathing
cells across transected spinal cord in several models has
resulted in axonal regeneration and restoration of con-
duction velocity [58-60].
Clinical implementation of olfactory ensheathing cells
for SCI has been reported in several trials. Lima et al trea-
ted 7 patients with ASIA class A traumatic-induced SCI
from C4-T6. All patients reported improvement in ASIA
motor scores, with 2 patient reporting return of sensation
to bladder and one gaining control of anal sphincter. The
therapy was well tolerated, however adverse effects
included a sensory decrease in one patient [5]. A subse-
quent study by Mackay-Sim et al [6] reported no major
benefit in a 3 year follow-up of patients with traumatic
injury to the thoracic spine (T4-T10) that occurred 6-36
months prior to therapeutic intervention. Three patients
were administered ex vivo expanded autologous olfactory
ensheath cells, and compared to 3 control patients. All
patients had a sustained and complete loss of sensory and
motor function below the injury, being classified as ASIA
Category A. Cells were administered into the damaged
area of the spinal cord, as well as at the proximal and dis-
tal ends of the intact cord subsequent to laminectomy and
durotomy. No improvement was observed in functional
parameters tested including ASIA motor and sensory
assessment, COVS, or FIMS. Radiological assessment was
unremarkable in the treated patients, indicating safety of
the procedure. One treated patient had an increased sensi-
tivity to light touch that was observed over 3 segments.
Schwann Cells
Schwann cells are terminally differentiated cells of the per-
ipheral nervous system whose main function is remyelina-
tion and promoting axonal regeneration. These cells have
been used experimentally since 1981 for the purpose of
accelerating healing post SCI [61]. Since then, numerous
animal studies have been conducted. In a comprehensive
review, Tetzlaff et al [62] discussed 35 rodent studies in
which the overall findings where that Schwann cells pos-
sessed ability to regenerate sensory axons from the dorsal
root ganglia and propriospinal axons adjacent to the injury
site. However the cells were incapable of healing brainstem
spinal axons, nor where they able to cause axons exit and
reenter the host spinal cord. Functionally, benefits in loco-
motion, and neurological parameters subsequent to
Schwann cell administration have been noted in SCI
induced by subacute contusion [63], photochemical
damage [64], and transection [65].
Schwann cell clinical trial
Schwann cells are attractive from a clinical perspective
because of the possibility of using autologous cells, thus
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dilemmas associated with material of fetal origin. Saberi
et al [7] reported preliminary results in 4 patients trea-
ted with autologous Schwann cells suffering from
chronic thoracic SCI. Schwann cells were isolated from
t h es u r a ln e r v ea n dg r o w ni nv i t r ow i t h o u tp a s s a g i n g .
They were injected into at a concentration of 3-4.5
million cells in a total volume of 300 uL into the injured
segment of the cord adjacent to the rostral and caudal
ends.
No adverse effects or functional improvements were
noted, nor was MRI capable of identifying transplanted
cells. One of four patients reported increased motor and
sensory improvement after treatment.
Bone marrow stem cells
Bone marrow mononuclear cells have been classically
used as a hematopoietic stem cell source for bone mar-
row transplantation, however some efficacy has been
demonstrated in accelerating healing in cardiac [66],
hepatic [67,68], and vascular injury [69,70]. Given the
bone marrow contains cells capable of providing trophic
support for neurons [71-74], as well as cells possibly
capable of directly differentiating into neurons [75,76], a
series of investigations have been performed in this area.
In animal models it has been demonstrated that bone
marrow mononuclear cells [74], CD34 hematopoietic
stem cells [77], mesenchymal stem cells [78-80], and in
vitro differentiated mesenchymal stem cells [81], all pos-
sess some level of SCI regenerative activity.
The dog is a very relevant large animal model of SCI.
In a comprehensive, blinded study of spinal cord com-
pressive injury in the dog, Jung et al. demonstrated a
biologically and statistically improved outcome with
therapy using autologous and allogeneic bone marrow
mesenchymal stem cells. MRI, histology, and immuno-
fluorescence supported the direct effect of the therapy
on repair of the SCI [79].
Administration of bone marrow mononuclear cells via
lumbar puncture in patients with spinal cord injury has
been demonstrated to induce no serious adverse effects
[ 8 2 ] .As t u d yo f8p a t i e n t sw i t hc h r o n i ca n da c u t eS C I
reported administration of bone marrow mononuclear
cells via intravenous route as well as into the spinal canal
and directly into the spinal cord. The authors observed
improvement in bladder function, as well as benefit using
the ASIA, Barthel (quality of life), Frankel, and Ashworth
instruments. Furthermore, it was stated that 52 SCI
patients have been treated with no serious adverse events
[2]. Another study examined 20 SCI patients complete
injury who were administered autologous bone marrow
mononuclear cells in an acute (10-30 days after injury)
and chronic (2-17 months after injury) setting. Improve-
ment in motor and/or sensory functions was observed
within 3 months in 5 of the 7 acute patients, and in 1 of
13 chronic patients. No adverse effects were reported
with 11 patients being followed up for more than 2 years
post stem cell administration [3]. Thus it appears that
autologous bone marrow cells have a favorable safety
profile, with some signal of efficacy, although larger
studies are required.
These approaches promoted a more aggressive proto-
col combining stem cell administration into the area of
injury, together with endogenous stem cell mobilization.
Yoon et al [4] assessed a total of 48 patients having com-
plete ASIA A SCI at the cervical or thoracic area that
were either a) untreated; b) treated 2 weeks or less after
the injury (acute); c) treated 2-8 weeks after the injury
(subacute); or d) treated more than 8 weeks after injury
(chronic). Treatment consisted of 10
8 autologous bone
marrow mononuclear cells administered in six injections
of 300-uL surrounding the lesion site with the injection
depth of 5 mm from the dorsal surface and 5 mm lateral
from the midline. The lesion was exposed by laminect-
omy one vertebra above to one below and the dura mater
was then incised, sparing the arachnoid, which was sub-
sequently opened separately with microscissors. GM-CSF
was administered in 5 monthly cycles of 5 daily injections
at the beginning of the month at a concentration of
250 g/m
2 of body surface area. Injection procedure was
uneventful, with adverse events being mild, typically con-
sistent with GM-CSF administration. An increased inci-
dence of neuropathic pain was observed in the subacute
and chronically treated patients as compared to acute
and control patients. Neurological improvement (AIS A
to AIS B or AIS C) was observed in 29.5% and 33.3% of
patients in the acute and sub-acute groups, respectively.
No improvement was noted in the chronic group, 7.7%
and 12.5% was observed in the control, and a historical
control [83], respectively. Changes in spinal diameter,
both increases and decreases occurred in the treated
groups as compared to untreated. Functional MRI studies
indicated regeneration of functional neural pathways in
some of the treated patients. Interestingly, a correlation
between response and GM-CSF induced leukocytosis was
observed. This study is a continuation of previous work
by the same group, Park et al. [84], in which 6 patients
with complete AIS grade A SCI were treated with an
identical protocol. Four of the patients went from AIS A
to C, one patient when from AIS A to B, and one had no
change.
Adipose-derived Stem and Progenitor Cells
Mesenchymal stem cells derived from adipose tissue have
been extensively described in the literature, including sig-
nificant support for the ability of these progenitors to dif-
ferentiate into many neural cell types [85-87]. In a similar
experiment to the canine SCI bone manuscript described
above [79], Ryu and et al [88], conducted a blinded, pla-
cebo controlled canine clinical study of SCI using and
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SCI with cells administered intralesionally one week after
SCI. The treated groups both statistically outperformed
the saline control group and showed significant clinical
and histological improvement in ambulation and cord
neural repair.
Cord Blood/Placental Derived Cells
Umbilical cord and Wharton’s jelly derived MSC offer
unique therapeutic characteristics in comparison to bone
marrow MSC. Specifically, longer telomeres, increased
passage ability without loss of differentiation potential,
and more potent cytokine release activity are some
attractive features of this cell population [89]. Yang et al
[90], generated a population of Wharton’s jelly derived
MSC and administered the cells alone or after treatment
with neural conditioned media for 3 or 6 days into
immunocompetent rats subsequent to complete spinal
cord transection. Improvements in locomotion were
observed in animals receiving MSC or MSC treated with
conditioned media. Regeneration of corticospinal tract
axons and neurofilament-positive fibers was observed.
Mechanistically, the cells appeared to function at least in
part by production of growth factors such as bFGF,
GITR, VEGFR3, neurotrophin-3, and NAP-2. Studies are
currently underway using combinations of factors such
as BDNF together with cord MSC to augment regenera-
tive activity post-SCI [91]. Clinically, a case report from
Korea describes the administration of multipotent cord
blood derived stem cells into a SCI patient by local injec-
tion. These cells elicited improvement in ability to move
hips and thighs, as well as augmented sensory activity 41
days after cell therapy. Radiologically documented regen-
eration of spinal cord and cauda equina was noted [92].
Cord blood derived cells have been described to sti-
mulate post-infarct neurogenesis through stimulation of
angiogenesis [44], preclinical studies have sought to
determine whether this may be replicated in conditions
of spinal cord injury. Using a rat left spinal cord hemi-
section model, Zhao et al demonstrated superiority
functional recovery according to the Tarlov score by
intraspinal administration of human CD34 cells derived
from cord blood versus bone marrow [93]. Both cell
populations where shown to survive and migrate into
the area of injury, as well as differentiate into glial
(GFAP+) or neural (NeuN+)-like cells. Purified CD34
cells from cord blood were demonstrated in another
study to augment functional recovery as assessed by the
Basso-Beattie-Bresnahan Locomotor Scale, reduce the
area of the cystic cavity at the site of injury, increase
white matter volume, and stimulate axonal regeneration
[94]. Mechanistically it appears that cord blood CD34
cells mediate effects in part through secretion of glial
cell line-derived neurotrophic factor (GDNF) and vascu-
lar endothelial growth factor (VEGF) [95].
Fetal/ES Derived Neural Progenitors
Fetal-derived neurons have been shown to survive, differ-
entiate and integrate into the host spinal cord after injury
[96]. When used together with scaffolds or ventral root
implants, these cells can grow their axons along the
whole length of the peripheral nerves to reach muscles in
the limb and restore function after transection [97]. In
addition to local placement of fetal neurons in the
damaged area, systemic administration of fetal neural
precursors results in local homing through a SDF-1 and
HGF-1-dependent mechanism [98]. Although numerous
experiments have demonstrated varying degrees of effi-
cacy in animal models [99-103], the risk of oncogenesis
raises concerns for clinical testing. These fears where
increased when an ataxia telangiectasia patient receiving
8-12 week old human fetal neuron preparations devel-
oped a multi-focal brain tumor containing donor cell kar-
yotype after transplantation [104]. Another concern has
been development of allodynia as a result of improper
nervous connections being made [105]. Embryonic stem
(ES) cells offer the ability to generate specific nervous
system cells useful for addressing various aspects of the
SCI process. For example, ES generated neural precursors
[106], motor neurons [107], and oligodendrocytes
[108,109] have all been used to induce amelioration of
SCI in animal models. Recently Geron Inc received an
FDA approval to initiate clinical trials using ES-derived
oligodendrocytes in SCI [110], which was subsequently
placed on clinical hold before patient treatment occurred
[111]. At present ES-based approaches are limited by
similar concerns as fetal stem cell based approaches in
terms of oncogenesis and allodynia.
Case Report: Informed Consent
Before administration of experimental intervention, the
p a t i e n ts i g n e da ni n f o r m e dc o n s e n tf o r mi nw h i c ht h e
experimental nature of the procedure to be performed
was explained in detail. Additionally the patient was
made aware of possible adverse events of the procedure,
including, but not limited to, increases in neuropathic
pain, possibility of ectopic tissue formation, and uncer-
tainty whether benefits will be obtained by the procedure.
The protocol was approved by the local Institutional
Review Board.
Case Report: Combination of Placental MSC and
Cord CD34
Currently stem cell clinical trials in SCI have been
focused on use of autologous bone marrow, MSC, or
olfactory ensheathing cells, with one case report of allo-
geneic cord derived multipotent progenitor cell [92]. The
possibility of using allogeneic stem cell sources would
allow for generation of standardized, “ready to use” cellu-
lar productions that could be widely implemented. While
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trials with safety being established [112], little work has
been reported on allogeneic CD34 cells in absence of
myeloablation/immune suppression. The authors have
recently published a series of 114 patients with neurode-
generative conditions treated with allogeneic non-
m a t c h e dc o r db l o o dc e l l s .W h i l en oa d v e r s ee v e n t sw e r e
associated with therapy, little is known about potential
efficacy of this approach [113]. The possibility of a com-
bination approach would be conceptually appealing given
that MSC are known anti-inflammatory and growth
factor producers, whereas CD34 cells produce angiogenic
factors and in some cases have been demonstrated to
differentiate into neurons directly. Here we describe a
protocol based on a combination of intrathecal adminis-
tration of CD34 and placental derived MSC.
The patient was born on November 5, 1979 and suf-
fered a spinal cord injury in a single propeller engine
airplane crash on May 13
th of 2008. At the time of the
accident he was diagnosed with an incomplete spinal
cord injury at the level T12 - L1, and crush fracture of
the L1 vertebral body which was described as a type A
in the ASIA scale. The patient was initially treated at
Hospital Mexico in Costa Rica on the day of the acci-
dent. The spine was stabilized using paravertebral rods
from T11 to L2. Bone fragments were removed from
the spinal canal. After 1 week of being hospitalized, he
Table 1 Administration Schedule
Date Route CD34 MSC
Cycle 1
Oct 31 2008 IT 3 million 6 million
Nov 11 2008 IT 3 million 6 million
Nov 14 2008 IT 3 million 6 million
Nov 18 2008 IT 3 million 6 million
Nov 20 2008 IT 3 million 6 million
Cycle 2
Jan 21 2009 IT 3 million 6 million
Jan 23 2009 IT 3 million 6 million
Jan 26 2009 IT 3 million 7 million
Jan 28 2009 IT 3 million 7 million
Jan 30 2009 IT 3 million 7 million
Cycle 3
Jul 1 2009 IT 1.5 million 5.7 million
Jul 3 2009 IT 1.5 million 6.3 million
July 6 2009 IT 1.5 million 6.3 million
IV 1.5 million 3.9 million
July 8 2009 IT 1.5 million 6.12 million
IV 1.5 million 3.9 million
July 10 2009 IT 1.5 million 6.12 million
Table 2 Muscle Strength evaluation by Groups*
Jun 16 2008 Nov 13 2008 Feb 23 2009 Aug 5 2009 Jan 7 2010
Right Left Right Left Right Left Right Left Right Left
Hips:
Flexors 1+ 2 2 4 2+ 5- 3- 5 3 5
Extensors 1+ 2 2 4 2 5 2+ 5 3- 5
Abductors 1+ 2 2 4- 2- 5 2 5 4 5
Adductors 1+ 3 2 4 2 5- 2+ 5 4 5
Internal Rotators 1+ 2- 1 4- 1+ 5- 3- 5 3 5
External Rotators 1 2 1 3+ 2- 5- 3- 5 3 5
Knee:
Flexors 1 2+ 1 4 1+ 4- 2 5- 3- 5
Extensors 1 4- 1 4- 2- 5 2 5 4 5
Ankle:
Dorsiflexors 0 4- 1- 4- 1 5 1- 5 1 5
Plantaflexors 1- 3- 3 4 3+ 5 3+ 5 3 5
Eversion 0 3- 1 4- 1 5 1+ 5 2 5
Inversion 0 3- 1 4- 1 5 1+ 5 2 5
Toes:
Flexors 0 4- 1 3+ 1 5 2- 5 1 5
Extensors 0 4- 0 3+ 1- 5 1+ 5 1 5
*Spinal cord injury occurred May 13, 2008. Patient received stem cell therapy Oct 31-Nov 20, 2008, Jan 21-Jan 30, 2009, and July 1-10, 2009.
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Costa Rica, where he remained for 4 weeks. He was
required to use a harness for lumbar support and had to
remain in the supine position and physical therapy
focused on stretching exercises. Neuropathic pain was
present at a 10/10 for which he was administered Lyrica
at 300 mg/day.
Cellular treatment was performed in 3 cycles between
Oct 31-Nov 20, 2008, Jan 21-30, 2009, and July 1-10,
2009 consisting of intrathecal administration of CD34
and MSC, with the last cycle also receiving IV injections
(Table 1). MSC and CD34 cells where isolated from the
placental matrix and cord blood, respectively, as pre-
viously described by us [114]. No adverse effects were
associated with the lumbar puncture procedure, nor
were immunological reactions or GVHD noted. A pro-
gressive improvement in muscle strength was noted
during the observation period, with last evaluation per-
formed in January of 2010 (Table 2). Additionally,
increased sensation in various dermatomes was noted as
shown in Table 3. As of January 7
th,2 0 1 0h ei sc a t e g o r -
ized as an ASIA D patient. He recovered urologic, sex-
ual and bowel function. The patient discontinued use of
Lyrica and reports occasional pain once a week at a
level of 3/10. Throughout the courses of cell treatments
the patient received physical therapy.
Spontaneous recovery of spinal cord injury patients has
been previously reported in the literature [115], which is
a concern for clinical trial design in this area [116]. How-
ever, recovery of bowel and sexual function in a patient
presenting with ASIA A injury is extremely rare. Given
that this study is a case report, we are cautious in the
interpretation of efficacy data. However, the demonstra-
tion of feasibility of intrathecal combination stem cell
administration, without occurrence of neuropathic pain
or ectopic tissue formation supports further investigation
of this approach in a standardized manner.
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